In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)

被引：0
|
作者：
Mohammad Haghighi
Leila Jahangard
Hamid Mohammad-Beigi
Hafez Bajoghli
Hassan Hafezian
Alireza Rahimi
Hamid Afshar
Edith Holsboer-Trachsler
Serge Brand
机构：
[1] Hamadan University of Medical Sciences,Research Center for Behavioral Disorders and Substances Abuse
[2] Isfahan University of Medical Sciences,Isfahan Psychosomatic Research Center
[3] Tehran University of Medical Sciences,Psychiatry and Psychology Research Center (PPRC), Roozbeh Hospital
[4] Psychiatric Hospital of the University of Basel,Center for Affective, Stress and Sleep Disorders (ZASS)
来源：
Psychopharmacology | 2013年 / 228卷
关键词：
Obsessive–compulsive disorder; Memantine; SSRIs; Double-blind trial; Placebo; Y-BOCS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：633 / 640
页数：7
相关论文
共 50 条
  • [31] Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients
    Kamijima, K
    Murasaki, M
    Asai, M
    Higuchi, T
    Nakajima, T
    Taga, C
    Matsunaga, H
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 58 (04) : 427 - 433
  • [32] Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
    Berlin, Heather A.
    Koran, Lorrin M.
    Jenike, Michael A.
    Shapira, Nathan A.
    Chaplin, William
    Pallanti, Stefano
    Hollander, Eric
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (05) : 716 - 721
  • [33] Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive- compulsive disorder: A double-blind placebo-controlled, randomized clinical trial
    Askari, Sanaz
    Mokhtari, Saba
    Shariat, Seyed Vahid
    Shariati, Behnam
    Yarahmadi, Masoomeh
    Shalbafan, Mohammadreza
    BMC PSYCHIATRY, 2022, 22 (01)
  • [34] A double-blind, placebo-controlled trial of folic acid addition in fluoxetine for treatment of obsessive-compulsive disorder
    Tural, O
    Corapçioglu, A
    Bosgelmez, S
    Köroglu, G
    Duman, C
    Önder, E
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S307 - S307
  • [35] Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive-Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
    Kishi, Taro
    Matsuda, Yuki
    Iwata, Nakao
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 (01) : 43 - 48
  • [36] A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder
    Soltani, Farhad
    Sayyah, Mehdi
    Feizy, Fariba
    Malayeri, Alireza
    Siahpoosh, Amir
    Motlagh, Ismail
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2010, 25 (06) : 509 - 513
  • [37] A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder resistant to serotonin reuptake inhibitors
    Denys, D
    Westenberg, H
    BIOLOGICAL PSYCHIATRY, 2004, 55 : 189S - 190S
  • [38] A double-blind, randomized, placebo-controlled trial of quetiapine augmentation in patients with obsessive-compulsive disorder resistant to serotonin reuptake inhibitors
    Denys, D
    De Geus, E
    Van Megen, H
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S361 - S361
  • [39] Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial
    Esalatmanesh, Sophia
    Abrishami, Zoha
    Zeinoddini, Atefeh
    Rahiminejad, Fatemeh
    Sadeghi, Majid
    Najarzadegan, Mohammad-Reza
    Shalbafan, Mohammad-Reza
    Akhondzadeh, Shahin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2016, 70 (11) : 517 - 526
  • [40] A double-blind, randomized, placebo-controlled trial of quetiapine augmentation in patients with obsessive-compulsive disorder resistant to serotonin reuptake inhibitors
    Denys, D
    de Geus, E
    van Megen, H
    Westenberg, H
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S196 - S196
12345